Venus Remedies Limited (VENUSREM) AI Stock Analysis

Venus Remedies Limited

(NSE:VENUSREM)

Select Model

Rating:81Outperform

Price Target:INR 1,423.00▲(15.53% Upside)

Action:reiterated

Date:09/06/26

Strong financial performance, with accelerating revenue, profitability, and cash flows plus a low-debt balance sheet, is the dominant positive driver. Supportive technicals with price above key averages add further strength, while fair valuation provides moderate contribution.

Positive Factors

Revenue GrowthA renewed growth trend across the latest three years indicates improving demand for the company’s pharmaceutical products and supports a stronger operating base. Continued top-line expansion can improve scale, fund research and commercialization, and reinforce its market position over the next several quarters.

Negative Factors

Limited Margin VisibilityThe strong 2026 earnings improvement is harder to assess as a durable trend because the available analysis does not establish how margins changed in that period. If profitability was affected by temporary factors, future earnings could normalize, reducing confidence in the pace of improvement.

Venus Remedies Limited (VENUSREM) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 16.56B
Dividend Yield: 0.82%
Average Volume (3M): 3,800
Price to Earnings (P/E): 13.6
Beta (1Y): 0.73
Revenue Growth: 20.22%
EPS Growth: 73.03%
Country: India
Employees: 1,472
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Venus Remedies Limited Business Overview & Revenue Model

Company Description

Venus Remedies Limited is a pharmaceutical enterprise engaged in the development, production, and global distribution of its medicinal products, serving both the Indian and international markets. The company's diverse portfolio addresses a wide spect...

Venus Remedies Limited Financial Statement Overview

Summary

Revenue and net income show strong recent growth with better margins; balance sheet is robust with minimal debt and rising equity; operating and free cash flows have improved markedly, indicating solid efficiency.

Income Statement

85Very Positive

Balance Sheet

92Very Positive

Cash Flow

88Very Positive

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	8.11B	7.70B	6.48B	5.91B	5.56B	5.99B
Gross Profit	3.25B	2.68B	1.66B	2.18B	2.25B	2.00B
EBITDA	1.75B	1.60B	944.10M	711.80M	703.46M	701.40M
Net Income	1.16B	1.03B	453.20M	284.91M	265.70M	407.24M
Balance Sheet
Total Assets	0	8.54B	7.16B	6.27B	6.01B	5.80B
Cash, Cash Equivalents and Short-Term Investments	1.03B	1.04B	1.64B	838.05M	720.77M	432.56M
Total Debt	0	124.10M	16.90M	413.25M	422.90M	428.45M
Total Liabilities	-6.64B	1.90B	1.55B	1.39B	1.41B	1.39B
Stockholders Equity	6.64B	6.64B	5.61B	4.88B	4.60B	4.40B
Cash Flow
Free Cash Flow	682.20M	1.20B	812.90M	278.40M	288.02M	272.94M
Operating Cash Flow	811.10M	1.57B	909.20M	372.85M	366.20M	410.01M
Investing Cash Flow	-1.27B	-1.84B	-807.90M	-72.09M	-508.30M	-166.26M
Financing Cash Flow	126.70M	-25.30M	-9.50M	-10.83M	-5.70M	-94.77M

Venus Remedies Limited Technical Analysis

Technical Analysis SentimentNegative

Last Price1231.75

Price Trends

50DMA1608.99Negative

100DMA1658.95Negative

200DMA1279.53Negative

Market Momentum

MACD-94.52Positive

RSI26.52Positive

STOCH2.53Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VENUSREM, the sentiment is Negative. The current price of 1231.75 is below the 20-day moving average (MA) of 1548.86, below the 50-day MA of 1608.99, and below the 200-day MA of 1279.53, indicating a bearish trend. The MACD of -94.52 indicates Positive momentum. The RSI at 26.52 is Positive, neither overbought nor oversold. The STOCH value of 2.53 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VENUSREM.

Venus Remedies Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:VENUSREM against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:VENUSREM	81Outperform	INR 16.46B	13.61	―	0.82%	20.22%	73.03%
IN:SYNCOMF	80Outperform	INR 18.09B	21.14	―	0.52%	0.44%	48.60%
IN:WINDLAS	68Neutral	INR 18.10B	27.61	―	0.72%	18.53%	1.89%
IN:LINCOLN	67Neutral	INR 10.05B	10.37	―	0.36%	10.20%	11.70%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:INDSWFTLAB	51Neutral	INR 31.95B	53.99	―	―	66.39%	-72.31%
IN:INDOCO	47Neutral	INR 19.23B	61.26	―	0.10%	10.75%	―

* General Sector Average

Performance Comparison

IN:VENUSREM and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:VENUSREM	Venus Remedies Limited	1231.75	791.09	179.52%
IN:INDOCO	Indoco Remedies Limited	208.35	-64.66	-23.68%
IN:INDSWFTLAB	Ind-Swift Laboratories Ltd.	367.40	265.25	259.67%
IN:LINCOLN	Lincoln Pharmaceuticals Ltd	501.95	-29.59	-5.57%
IN:SYNCOMF	Syncom Formulation (India) Ltd.	19.25	2.69	16.26%
IN:WINDLAS	Windlas Biotech Ltd.	877.25	-76.09	-7.98%

Venus Remedies Limited Corporate Events

Venus Remedies Secures Shareholder Approval for All Resolutions at 37th AGM

Aug 21, 2026

Venus Remedies Limited has announced that all 12 resolutions proposed at its 37th Annual General Meeting, held on August 20, 2026 via video conferencing, were approved by the requisite majority under SEBI listing regulations and the Companies Act. Th...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 06, 2026

Venus Remedies Limited AI Stock Analysis